Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 68; no. 4; p. 396
• Main Authors: Funderburg, Nicholas T, Jiang, Ying, Debanne, Sara M, Labbato, Danielle, Juchnowski, Steven, Ferrari, Brian, Clagett, Brian, Robinson, Janet, Lederman, Michael M, McComsey, Grace A
• Format: Journal Article
• Language: English
• Published: United States 01.04.2015
• Subjects: Adult; Anti-Retroviral Agents - therapeutic use; Anticholesteremic Agents - therapeutic use; Antigens, CD - analysis; Female; Fluorobenzenes - therapeutic use; HIV Infections - drug therapy; HIV Infections - pathology; HLA-DR Antigens - analysis; Humans; Male; Middle Aged; Monocytes - chemistry; Monocytes - immunology; Programmed Cell Death 1 Receptor - analysis; Pyrimidines - therapeutic use; Rosuvastatin Calcium; Sulfonamides - therapeutic use; T-Lymphocytes - chemistry; T-Lymphocytes - immunology; Treatment Outcome; Vasculitis - pathology; Vasculitis - prevention & control

Despite suppressive antiretroviral therapy (ART), increased levels of immune activation persist in HIV-infected subjects. Statins have anti-inflammatory effects and may reduce immune activation in HIV disease. Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV)...